Glucocorticoids and Pulmonary Hypertension

• Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia; Bronchopulmonary Dysplasia; Pulmonary Hypertension

• Registration Number: NCT04499196
• Lead Sponsor: Washington University School of Medicine

Brief Summary

Pediatric idiopathic pulmonary hypertension has significant morbidity and mortality. An ever expanding body of knowledge indicates the important contribution of inflammation to pathogenesis and successful treatment with glucocorticoids. Over the last several years the investigators have utilized steroids in patients with severe pulmonary hypertension as part of a treatment regimen. These basic science studies possibly identifies a biochemical etiology for the development of disease and may also be impacted by the administration of steroids. Additionally, there is a commercially available assay which tests for all of the above molecules.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-29
• Study First Submitted: 2020-07-30
• Study First Submitted QC: 2020-07-30
• Study First Posted: 2020-08-05
• Status Verified: 2022-03
• Last Update Submitted: 2022-03-17
• Last Update Posted: 2022-03-31
• Primary Completion: 2022-07-29
• Study Completion: 2022-07-29

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• premature, BPD, >36 wga
• pulmonary hypertension evidence by echocardiogram

Exclusion Criteria

• poor ventilation/oxygenation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Echo estimation of RV pressure	5 days

Trial Locations

Locations (1)

St. Louis Children's Hospital; 🇺🇸 Saint Louis, Missouri, United States